Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06687551 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

JAK Inhibitor Dose TAPering Strategy Study

Study acronym: JAK-TAP
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Start date changed from estimate of Jan 1, 2025 to Jun 6, 2025 · Trial sites expanded: 0 → 24 locationsv2 Show 2 more changesShow less
    • Start date changed from estimate of Jan 1, 2025 to Jun 6, 2025
    • Trial sites expanded: 0 → 24 locations
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study aims to assess the feasibility of tapering JAK inhibitors in rheumatoid arthritis patients in low disease activity by comparing a group of patients tapering the JAK inhibitor dosage to a group of patients continuing the full-dose. Participants will: * Either take 1. JAK inhibitor dose-tapering strategy. 2. JAK inhibitor continuous therapy strategy. * Visit the clinic once every 3 months for checkups and tests * Keep a diary of their treatment intake and symptoms
Trial Details
NCT Number NCT06687551
Lead Sponsor University Hospital, Toulouse
Conditions Rheumatoid Arthritis (RA
Enrollment 308 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov